AbCellera Biologics Inc.
(ABCL)
undefined
undefined%
At close: undefined
2.80
-0.18%
After-hours Dec 13, 2024, 07:55 PM EST
Company Description
AbCellera Biologics Inc. develops antibody discovery platform.
Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs.
As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners.
AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company.
The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics Inc.
| Country | CA |
| IPO Date | Dec 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 586 |
| CEO | Dr. Carl L.G. Hansen Ph.D. |
Contact Details
Address: 2215 Yukon Street Vancouver, BC CA | |
| Website | https://www.abcellera.com |
Stock Details
| Ticker Symbol | ABCL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001703057 |
| CUSIP Number | 00288U106 |
| ISIN Number | CA00288U1066 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carl L.G. Hansen Ph.D. | Chief Executive Officer, President & Chairperson |
| Andrew Booth M.B.A. | Chief Financial Officer |
| Dr. Ester Falconer Ph.D. | Chief Technology Officer |
| Tryn T. Stimart Esq., J.D., M.Sc. | Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer |
| Marcie Thiessen CPA, CGA | Senior Director of Finance & Accounting |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 05, 2024 | 4 | Filing |
| Nov 26, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 04, 2024 | 10-Q | Quarterly Report |
| Nov 04, 2024 | 8-K | Current Report |
| Oct 09, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Sep 24, 2024 | 4 | Filing |
| Aug 29, 2024 | 4 | Filing |
| Aug 06, 2024 | 10-Q | Quarterly Report |
| Aug 06, 2024 | 8-K | Current Report |